Appropriate,timely, and rational treatment of type 2 diabetes mellitus: Meeting the challenges of primary care |
| |
| Authors: | Jeff Unger Christopher G. Parkin |
| |
| Affiliation: | 1. Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA;2. Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA;3. Pfizer Inc., 1 Burtt Road, Andover, MA 01810, USA;4. Janssen Research and Development LLC, 3210 Merryfield Row, San Diego, CA 92121, USA;5. Janssen Research and Development LLC, 1400 McKean Road, Spring House, PA 19477, USA;6. Roche, Pharma Research and Early Development Informatics, Roche Innovation Center, New York, NY, 10016, USA;7. Roche, Pharma Research and Early Development Informatics, Roche Innovation Center, Penzberg 82377, Germany;8. Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA 92093, USA;1. Maternal and Fetal Health Research Centre, University of Manchester, St. Mary’s Hospital, Oxford Road, Manchester M13 9WL, United Kingdom;2. School of Electrical and Electronic Engineering, University of Manchester, Sackville Street Building, Manchester M13 9PL, United Kingdom;3. School of Materials, University of Manchester, Oxford Road, M13 9PL, United Kingdom;1. Hospital de Especialidades, Centro Medico Nacional de Occidente, Mexican Institute of Social Security, Guadalajara, Mexico;2. CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), PAHO/WHO Collaborating Centre for Diabetes, Facultad de Ciencias Médicas UNLP, La Plata, Argentina;3. Centro de Especialidades Medicas de Celaya, Latin University of Mexico in Celaya, Guanajuato, Mexico;4. Institute for Children with Diabetes in Porto Alegre and the Brazilian Diabetes Society, Porto Alegre, Brazil |
| |
| Abstract: | Diabetes now affects >24 million people in the United States. As the prevalence of diabetes continues to increase, long-term complications of diabetes have emerged as major health care issues. Although much focus has been placed on diabetes, it is important to note that prediabetes, the intermediate state of type 2 diabetes mellitus (DM), is not benign. The progression to type 2 DM for patients with impaired glucose tolerance (IGT) is 6% to 10% per year; for persons with both impaired fasting glucose and IGT, the cumulative incidence of diabetes in 6 years may be as high as 60%. Given the significant clinical and financial impact of both conditions, it is vital that clinicians initiate treatment of diabetes and prediabetes early and aggressively. Despite advances in diabetes treatment, many health care providers do not initiate or intensify therapy appropriately during patient visits, which contributes to poor diabetes control. Although management of blood pressure and lipid levels can be complex, glycemic control is often problematic for patients and their clinicians. Thus, clinicians must learn to use the various pharmacologic and nonpharmacologic strategies effectively to achieve glucose targets in their patients with type 2 DM. Patients with prediabetes should be managed with a combination of lifestyle intervention and appropriately timed pharmacotherapy. Pancreatic β-cell preservation should be a primary metabolic target. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
